IL312328A - Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidance - Google Patents
Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidanceInfo
- Publication number
- IL312328A IL312328A IL312328A IL31232824A IL312328A IL 312328 A IL312328 A IL 312328A IL 312328 A IL312328 A IL 312328A IL 31232824 A IL31232824 A IL 31232824A IL 312328 A IL312328 A IL 312328A
- Authority
- IL
- Israel
- Prior art keywords
- cbd
- use according
- subject
- irritability
- asd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271015P | 2021-10-22 | 2021-10-22 | |
| PCT/US2022/078449 WO2023070045A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312328A true IL312328A (en) | 2024-06-01 |
Family
ID=84358575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312328A IL312328A (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidance |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240342198A1 (enExample) |
| EP (1) | EP4419091A1 (enExample) |
| JP (1) | JP2024536581A (enExample) |
| KR (1) | KR20240093852A (enExample) |
| CN (1) | CN118284412A (enExample) |
| AU (1) | AU2022373753A1 (enExample) |
| CA (1) | CA3235677A1 (enExample) |
| IL (1) | IL312328A (enExample) |
| MX (1) | MX2024004766A (enExample) |
| WO (1) | WO2023070045A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| WO2010127033A1 (en) | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| CA3300266A1 (en) * | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| WO2019224824A1 (en) * | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| JP7856584B2 (ja) * | 2020-05-26 | 2026-05-11 | ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド | カンナビジオールを用いた自閉症スペクトラム障害の処置 |
| TWI902836B (zh) * | 2020-06-29 | 2025-11-01 | 美商和諧生物科學管理股份有限公司 | 以大麻二酚(cannabidiol)治療X染色體脆折症候群 |
| LT4243797T (lt) * | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
-
2022
- 2022-10-20 CN CN202280077354.9A patent/CN118284412A/zh active Pending
- 2022-10-20 MX MX2024004766A patent/MX2024004766A/es unknown
- 2022-10-20 IL IL312328A patent/IL312328A/en unknown
- 2022-10-20 WO PCT/US2022/078449 patent/WO2023070045A1/en not_active Ceased
- 2022-10-20 KR KR1020247016925A patent/KR20240093852A/ko active Pending
- 2022-10-20 JP JP2024523674A patent/JP2024536581A/ja active Pending
- 2022-10-20 AU AU2022373753A patent/AU2022373753A1/en active Pending
- 2022-10-20 CA CA3235677A patent/CA3235677A1/en active Pending
- 2022-10-20 EP EP22803457.5A patent/EP4419091A1/en active Pending
-
2024
- 2024-04-22 US US18/642,059 patent/US20240342198A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024536581A (ja) | 2024-10-04 |
| CN118284412A (zh) | 2024-07-02 |
| CA3235677A1 (en) | 2023-04-27 |
| WO2023070045A1 (en) | 2023-04-27 |
| MX2024004766A (es) | 2024-06-11 |
| US20240342198A1 (en) | 2024-10-17 |
| AU2022373753A1 (en) | 2024-05-09 |
| KR20240093852A (ko) | 2024-06-24 |
| EP4419091A1 (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534362A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| WO2019224824A1 (en) | Cannabis-based compositions for the treatment of autistic spectrum disorders | |
| WO2021178579A1 (en) | Cannabis treatment of insomnia, pain, and skin conditions | |
| Wojcikowski et al. | New concepts of chronic pain and the potential role of complementary therapies | |
| CN107670027B (zh) | 治疗皮肤病况的组合物和方法 | |
| IL299399A (en) | Treatment of fragile X syndrome with cannabidiol | |
| Chottawornsak et al. | Topical 2% ketoconazole cream monotherapy significantly improves adult female acne: A double‐blind, randomized placebo‐controlled trial | |
| Babaee et al. | Therapeutic effects of Zataria Multiflora essential oil on recurrent oral aphthous lesion | |
| JP2024536581A5 (enExample) | ||
| Azimaraghi et al. | BOTH oral passiflora incarnata and oxazepam can reduce pre-operative anxiety in ambulatory surgery patients: A double-blind, placebo-controlled study | |
| WO2025137652A3 (en) | Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders | |
| MX2025000038A (es) | Composiciones farmacéuticas que comprenden isotretinoína y procesos para la preparación y usos de las mismas | |
| US11458160B2 (en) | Food supplements for use in the prophylaxis and treatment of migraine | |
| CN116712443A (zh) | 一种抑制氧化应激损伤的组合物及其应用 | |
| ES2581180B1 (es) | Uso de aloe oral para la mejora capilar | |
| JP5380930B2 (ja) | 睡眠改善剤 | |
| Nguyen Huu et al. | Efficacy of 10% Potassium Hydroxide Solution Versus 10% Salicylic Acid Ointment in Treatment of Molluscum Contagiosum-the Low-Cost Dermatologic Therapy in Vietnam. Open Access Maced J Med Sci. 2019 Jan 30; 7 (2): 269-271 | |
| Miranda-Massari et al. | Expediting COVID-19 Recovery with an Orthomolecular Approach: Two Case Reports | |
| Van et al. | COMPARATION OF THE EFFICACY OF ORAL IVERMECTIN COMBINED TOPICAL METRONIDAZOL 1% WITH ORAL AND TOPICAL | |
| Sau Nguyen Huu et al. | Efficacy of 10% potassium hydroxide solution versus 10% salicylic acid ointment in treatment of molluscum contagiosum-the low-cost dermatologic therapy in Vietnam. | |
| CN103784627A (zh) | 一种治疗风热血燥型脂溢性皮炎的中药组合物 | |
| CA3112722A1 (en) | Nutraceutical composition for management of coronavirus | |
| Chutko et al. | Chronic tic disorders in children and adolescents and their treatment with adaptol | |
| CN101229231A (zh) | 附红细胞体病用兽用复方丁香搽剂及其制备方法 | |
| HK40029032A (en) | Food supplements for use in the prophylaxis and treatment of migraine |